Semax + Selank
Russian nootropic and anti-anxiety peptide pair
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The combination has not been studied. There is no trial, no case series, and no pharmacokinetic work examining Semax and Selank taken together, so any claim of synergy between them is inference rather than finding. What exists is a separate literature for each, almost entirely Russian, mostly small, and rarely blinded to Western standards. Semax has Russian clinical use in acute ischaemic stroke and cognitive impairment, supported by trials that have not been independently replicated outside Russia and that Western reviewers have generally judged too limited in quality to be conclusive. Selank has small Russian studies in generalised anxiety disorder and neurasthenia, including work associated with Zozulya and colleagues, again without independent replication. Beneath both sits a much larger animal literature on BDNF expression, monoamine turnover, and enkephalin degradation, which is mechanistically interesting and does not establish human effect. Nothing in either body of evidence tells you whether combining them adds benefit, cancels out, or interacts. Reported subjective effects come from self-experimenters, an uncontrolled and heavily confounded source.
- FDA
- The US Food and Drug Administration has not approved Semax or Selank for any use. They are not recognized US medicines. They are registered medicines in Russia.
- WADA
- Allowed
Reference only. Not medical advice.
What can go wrong
PROMINENT RISK: Neither peptide is FDA-approved; US supply is unregulated research-chemical material with uncertain purity, dose, and sterility. Human evidence is limited, mostly small Russian trials not independently replicated in the West. Long-term safety is not established. Nasal and injectable use of non-sterile product carries infection risk. Not a substitute for evaluated treatment of stroke, attention disorders, or anxiety.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Semax + Selank. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
Semax and Selank are two short synthetic peptides (small chains of amino acids, the building blocks of proteins) designed by Russian scientists. Semax is built from a piece of adrenocorticotropic hormone (ACTH, a natural signaling hormone) with an added tail that keeps it from breaking down quickly; it is used in Russia for stroke recovery and attention. Selank is built from tuftsin, a natural peptide of the immune system, and is used in Russia as an anti-anxiety (anxiolytic) agent that reportedly does not cause sedation or dependence. People often combine the two, using Semax for focus and memory and Selank for calm, taking both as nasal sprays. Both are registered medicines in Russia but have never been approved by the US Food and Drug Administration or the European Medicines Agency. Most human studies were done in Russia, are small, and were published largely in Russian-language journals, so independent Western confirmation is limited. In the US they circulate as research chemicals from unregulated suppliers, meaning purity and dose are not guaranteed.
russian nootropic pair
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Safety in detail
Neither peptide is approved by the US Food and Drug Administration or the European Medicines Agency, and neither appears on any Western pharmacopoeia. Their legal home is Russia and a handful of neighbouring states, where they are prescription nasal medicines. Elsewhere they reach buyers as research chemicals, which means the label is the only evidence of what is inside, and independent testing of grey-market peptides has repeatedly found underfilled, degraded, or mislabelled product. Neither substance appears on the World Anti-Doping Agency Prohibited List, though athletes should note that unlisted is not the same as tested and cleared, and contaminated product can still trigger a positive. What is genuinely unknown is the combination itself. No dose-ranging, interaction, or long-term safety data exist for using the two together.
What people get wrong
Often saidMyth: Decades of Russian use prove it works for everyone.
ActuallyReality: Russian approval and use are real, but the supporting trials are small and mostly not replicated to Western regulatory standards; long use is not the same as proof.
Often saidMyth: What you buy in the US is the same as the Russian medicine.
ActuallyReality: US supply is unregulated research-chemical material of uncertain purity and dose, not the registered Russian product.
Who profits, and who pushes back
Western evidence-based clinicians
The trials are small, mostly Russian, and not independently replicated to Western standards.
Drug regulators (FDA/EMA)
Neither peptide has been approved; safety and efficacy have not been established in their review.
Anti-doping and quality testers
Research-chemical sourcing means buyers cannot verify what is in the vial.
Nootropic supplement vendors
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Market Semax and Selank as a focus-plus-calm stack; profit from sales
Biohacker and longevity influencers
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Often use affiliate codes; mix genuine belief with paid promotion
Some Russian clinicians
Cite domestic approval and decades of local use
Where the research comes from
Most of the published research on this comes from one place. 55% of it is from Russia and former Soviet states. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Russia and former Soviet states | 55% |
| North America | 25% |
| Europe | 12% |
| Other | 8% |
Research published from: Russia.
How we got here
Semax and Selank both trace to a single building in Moscow, the Institute of Molecular Genetics of the Russian Academy of Sciences, and to the school of Ivan Ashmarin and Nikolai Myasoedov. Semax grew out of work on the ACTH(4,10) fragment, trimmed to ACTH(4,7) and stabilised with a Pro-Gly-Pro tail, which is why chemists sometimes write it as ACTH(4-7)-PGP or as its peptide sequence Met-Glu-His-Phe-Pro-Gly-Pro. Selank came later from the same institute, engineered from the immune peptide tuftsin with the same Pro-Gly-Pro trick appended, and it carries the internal research designation TP-7 in some Russian papers. Both circulate in Russia and several post-Soviet countries as registered nasal preparations, Semax typically as 0.1 percent or 1 percent drops and Selank as a 0.15 percent spray, sold under Cyrillic brand names that transliterate inconsistently. The pairing of the two is not a Russian clinical protocol. It was assembled by English-speaking nootropics communities in the late 2000s and 2010s, notably on Reddit and Longecity, where the appeal was pairing a stimulating peptide with a calming one. Vendors then packaged the two together as a bundle, which cemented the name. No published trial designed the combination.
Semax was created in the early 1980s at the Institute of Molecular Genetics of the (then Soviet) Academy of Sciences in Moscow by the groups of Ivan P. Ashmarin and Nikolai F. Myasoedov, who sought an ACTH-derived peptide with brain effects but without hormonal (cortisol-raising) action. Semax was registered as a medicine in Russia in 1994 and is on the Russian list of essential drugs for stroke and cognitive impairment. Selank was developed in the 1990s under Myasoedov at the same institute, engineered from the natural immune peptide tuftsin with an added Pro-Gly-Pro tail for stability, and is used in Russia as an anti-anxiety agent. What is validated: the Russian origin, the chemistry, and domestic regulatory approval. What is not validated: broad efficacy claims to Western regulatory standards, since large independent non-Russian trials are lacking.
- 1982Semax developed at the Institute of Molecular Genetics, Moscow (Ashmarin and Myasoedov)
- 1994Semax registered as a medicine in Russia
- 1990sSelank developed at the same institute under Myasoedov
- 2000sRussian clinical reports describe Selank's anti-anxiety effects
- 2010sBoth peptides spread to Western nootropic and biohacker communities as research chemicals
- 2026US FDA compounding advisory review of Semax scheduled
At a glance
- Form
- Intranasal drops or spray, used in Russia
- Semax base
- Fragment of the hormone ACTH plus a stabilizing tail
- Selank base
- Analog of the immune peptide tuftsin
- US status
- Not FDA-approved; research-chemical market
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Semax + Selank. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
Semax and Selank are not approved by the FDA for any indication and are not recognised US drugs.
Neither Semax nor Selank appears on the WADA Prohibited List, though unlisted status does not remove contamination risk for tested athletes.
Selank was assessed in small Russian clinical work for generalised anxiety disorder and neurasthenia, without independent Western replication.
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (indexed in PubMed)
Semax is derived from the ACTH(4,7) fragment with a Pro-Gly-Pro extension for metabolic stability, and Selank from tuftsin with the same modification.
No registered or completed clinical trial evaluates Semax and Selank as a combination.
Neither peptide holds a marketing authorisation in the European Union.
Unapproved peptide products sold as research chemicals carry documented risks of mislabelling, impurity, and non-sterility.